Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2results about How to "Simple price" patented technology

Label-free magnetic self-assembly nano-probe, construction method thereof and application of label-free magnetic self-assembly nano-probe in detection of PrPC protein

The invention provides a label-free magnetic self-assembly nanoprobe, a construction method thereof and application of the label-free magnetic self-assembly nanoprobe in detection of PrPC protein. The label-free magnetic self-assembly nanoprobe disclosed by the invention comprises a magnetic Fe3O4 / Fe2O3 (at) Au heteroplasmon nanorod array and a sulfhydrylation aptamer nucleic acid chain which is combined with the magnetic Fe3O4 / Fe2O3 (at) Au heteroplasmon nanorod array through an Au-S bond; a biosensor prepared from the label-free magnetic self-assembly nanoprobe is good in reproducibility and stability; the RSD value of multiple times of detection (intraday / day) is 1.55%; the storage time of multiple groups of sensors is 0-15 days, and the change of response signal values does not exceed 4%; the biosensor has a relatively low detection limit (1pg / mL), a relatively wide linear range (1 * 10 < pg / mL >-1 * 10 < 5 > pg / mL) and relatively good sensitivity, has very good application in detection of PrPC, and has very good practicability.
Owner:JIANGSU UNIV

A process for the synthesis of a remegapant intermediate

This invention discloses a method for synthesizing an intermediate of retinoic acid, relating to the field of pharmaceutical organic synthesis technology, comprising the following steps: S1, in the presence of a base, 2-amino-3-chloropyridine and 4-bromopiperidine undergo a nucleophilic substitution reaction in solvent A to prepare compound III; S2, in the presence of a catalyst and ammonia solution, compound III undergoes an amination reaction in solvent B to prepare compound II; S3, compound II is dissolved in solvent C, and sequentially undergoes CDI cyclization and hydrogen chloride solution salt formation to prepare compound I, namely 1-(piperidin-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. This invention is low-cost, uses mild reaction conditions, has a simple synthesis process, high yield, and eliminates the need for expensive and potentially unsafe excipients, effectively improving reaction safety, being environmentally friendly, and suitable for industrial production.
Owner:NANTONG CHANGYOO PHARMATECH CO LTD